"Dul\u00ED\u010Dek, Petr" . "6" . "Pavl\u00EDk, Tom\u00E1\u0161" . . "11150" . "In the Czech Republic, anagrelide (Thromboreductin) [29] is used according to the recommendations of the Czech Working Group on Myeloproliferative Disorders (CZEMP) for treatment of thrombocythemia associated with Ph-negative myeloproliferative disorders (MPDs). The patient data are collected in the Registry of patients with essential thrombocythemia (ET) and thrombocythemia associated with other MPDs treated with Thromboreductin. There were more haemorrhagic events during F-U: 109 events in 83 patients. Upon comparison of the number of events during F-U to their numbers in history, we found a two-fold decrease in arterial thrombosis, an almost two-fold decrease in microvascular thrombosis and even a 6.6-fold decrease in venous thromboembolism events."@en . "Ovesn\u00E1, Petra" . "Kissov\u00E1, Jarmila" . "The effectiveness of anagrelide treatment in patients with Ph-negative myeloproliferative diseases: Influence on the incidence of thrombosis in the data from the Registry of patients with essential thrombocythemia and thrombocythemia associated with other myeloproliferative diseases treated with Thromboreductin(R) to the end of 2012"@en . . . "59" . . . "112343" . "Schwarz, Ji\u0159\u00ED" . "RIV/00216208:11150/13:10189443" . "Posp\u00ED\u0161ilov\u00E1, Dagmar" . "\u00DA\u010Dinnost l\u00E9\u010Dby anagrelidem u nemocn\u00FDch s Ph-negativn\u00EDmi myeloproliferativn\u00EDmi chorobami: Ovlivn\u011Bn\u00ED v\u00FDskytu tromb\u00F3zy ve v\u00FDstupech Registru pacient\u016F s diagn\u00F3zou esenci\u00E1ln\u00ED trombocytemie a trombocytemie prov\u00E1zej\u00EDc\u00ED jin\u00E9 myeloproliferativn\u00ED onemocn\u011Bni l\u00E9\u010Den\u00FDch Thromboreductinem(R) ke konci roku 2012" . "0042-773X" . . "\u010Cerv\u00EDnek, Libor" . "The effectiveness of anagrelide treatment in patients with Ph-negative myeloproliferative diseases: Influence on the incidence of thrombosis in the data from the Registry of patients with essential thrombocythemia and thrombocythemia associated with other myeloproliferative diseases treated with Thromboreductin(R) to the end of 2012"@en . . . . . "8"^^ . "Thrombosis; Patient registry; Myeloproliferative disorders; Anagrelide (Thromboreductin(R))"@en . "Anagrelid (Thromboreductin(R)) [29] je v \u010CR pou\u017E\u00EDv\u00E1n dle doporu\u010Den\u00ED \u010Cesk\u00E9 pracovn\u00ED skupiny pro myeloproliferativn\u00ED choroby (CZEMP) k l\u00E9\u010Db\u011B trombocytemie prov\u00E1zej\u00EDc\u00ED Ph-negativn\u00ED chronick\u00E9 myeloproliferace (MPO). \u00DAdaje o nemocn\u00FDch jsou shroma\u017E\u010Fov\u00E1ny v Registru pacient\u016F s dia-gn\u00F3zou esenci\u00E1ln\u00ED trombocytemie a trombocytemie prov\u00E1zej\u00EDc\u00ED jin\u00E9 myeloproliferativn\u00ED onemocn\u011Bn\u00ED l\u00E9\u010Den\u00FDch Thromboreductinem(R) (d\u00E1le jen Registr). Jedn\u00EDm z nejv\u00FDznamn\u011Bj\u0161\u00EDch ukazatel\u016F \u00FAsp\u011B\u0161nosti l\u00E9\u010Dby je ovlivn\u011Bn\u00ED v\u00FDskytu klinick\u00E9 symptomatologie, p\u0159edev\u0161\u00EDm v\u00FDskytu trombotick\u00FDch projev\u016F. O \u00FAsp\u011B\u0161nosti l\u00E9\u010Dby, resp. komplexn\u00ED p\u00E9\u010De o nemocn\u00E9, sv\u011Bd\u010D\u00ED dvojn\u00E1sobn\u00FD pokles arteri\u00E1ln\u00ED tromb\u00F3zy, tak\u0159ka dvojn\u00E1sobn\u00FD pokles mikrovaskul\u00E1rn\u00ED tromb\u00F3zy a dokonce 6,6n\u00E1sobn\u00FD pokles p\u0159\u00EDhod \u017Eiln\u00EDho tromboembolizmu." . "Vnit\u0159n\u00ED l\u00E9ka\u0159stv\u00ED" . "\u00DA\u010Dinnost l\u00E9\u010Dby anagrelidem u nemocn\u00FDch s Ph-negativn\u00EDmi myeloproliferativn\u00EDmi chorobami: Ovlivn\u011Bn\u00ED v\u00FDskytu tromb\u00F3zy ve v\u00FDstupech Registru pacient\u016F s diagn\u00F3zou esenci\u00E1ln\u00ED trombocytemie a trombocytemie prov\u00E1zej\u00EDc\u00ED jin\u00E9 myeloproliferativn\u00ED onemocn\u011Bni l\u00E9\u010Den\u00FDch Thromboreductinem(R) ke konci roku 2012"@cs . "16"^^ . "[CB9B0A08A1FD]" . "Penka, Miroslav" . . "\u00DA\u010Dinnost l\u00E9\u010Dby anagrelidem u nemocn\u00FDch s Ph-negativn\u00EDmi myeloproliferativn\u00EDmi chorobami: Ovlivn\u011Bn\u00ED v\u00FDskytu tromb\u00F3zy ve v\u00FDstupech Registru pacient\u016F s diagn\u00F3zou esenci\u00E1ln\u00ED trombocytemie a trombocytemie prov\u00E1zej\u00EDc\u00ED jin\u00E9 myeloproliferativn\u00ED onemocn\u011Bni l\u00E9\u010Den\u00FDch Thromboreductinem(R) ke konci roku 2012" . "CZ - \u010Cesk\u00E1 republika" . "Anagrelid (Thromboreductin(R)) [29] je v \u010CR pou\u017E\u00EDv\u00E1n dle doporu\u010Den\u00ED \u010Cesk\u00E9 pracovn\u00ED skupiny pro myeloproliferativn\u00ED choroby (CZEMP) k l\u00E9\u010Db\u011B trombocytemie prov\u00E1zej\u00EDc\u00ED Ph-negativn\u00ED chronick\u00E9 myeloproliferace (MPO). \u00DAdaje o nemocn\u00FDch jsou shroma\u017E\u010Fov\u00E1ny v Registru pacient\u016F s dia-gn\u00F3zou esenci\u00E1ln\u00ED trombocytemie a trombocytemie prov\u00E1zej\u00EDc\u00ED jin\u00E9 myeloproliferativn\u00ED onemocn\u011Bn\u00ED l\u00E9\u010Den\u00FDch Thromboreductinem(R) (d\u00E1le jen Registr). Jedn\u00EDm z nejv\u00FDznamn\u011Bj\u0161\u00EDch ukazatel\u016F \u00FAsp\u011B\u0161nosti l\u00E9\u010Dby je ovlivn\u011Bn\u00ED v\u00FDskytu klinick\u00E9 symptomatologie, p\u0159edev\u0161\u00EDm v\u00FDskytu trombotick\u00FDch projev\u016F. O \u00FAsp\u011B\u0161nosti l\u00E9\u010Dby, resp. komplexn\u00ED p\u00E9\u010De o nemocn\u00E9, sv\u011Bd\u010D\u00ED dvojn\u00E1sobn\u00FD pokles arteri\u00E1ln\u00ED tromb\u00F3zy, tak\u0159ka dvojn\u00E1sobn\u00FD pokles mikrovaskul\u00E1rn\u00ED tromb\u00F3zy a dokonce 6,6n\u00E1sobn\u00FD pokles p\u0159\u00EDhod \u017Eiln\u00EDho tromboembolizmu."@cs . . "I" . . . "\u00DA\u010Dinnost l\u00E9\u010Dby anagrelidem u nemocn\u00FDch s Ph-negativn\u00EDmi myeloproliferativn\u00EDmi chorobami: Ovlivn\u011Bn\u00ED v\u00FDskytu tromb\u00F3zy ve v\u00FDstupech Registru pacient\u016F s diagn\u00F3zou esenci\u00E1ln\u00ED trombocytemie a trombocytemie prov\u00E1zej\u00EDc\u00ED jin\u00E9 myeloproliferativn\u00ED onemocn\u011Bni l\u00E9\u010Den\u00FDch Thromboreductinem(R) ke konci roku 2012"@cs . . "1"^^ . . "RIV/00216208:11150/13:10189443!RIV14-MSM-11150___" .